Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247652 | 0.81 | GRM5 (0.45) | KDM4EALDH1A1HPGDHSD17B10HSD11B1 | |
| SCHEMBL31247691 | 0.76 | TNNI3K (0.42) | KDM4EALDH1A1HPGDHSD17B10HSD11B1 | |
| SCHEMBL31247692 | 0.76 | AURKA (0.47) | BACE1JAK2JAK1TYK2JAK3 | |
| SCHEMBL12017942 | 0.76 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDHSD17B10GLO1 | |
| SCHEMBL31247510 | 0.74 | TYK2 (0.48) | KDM4EALDH1A1HPGDHSD17B10HSD11B1 | |
| SCHEMBL31300246 | 0.73 | TYK2 (0.53) | KDM4EALDH1A1HPGDHSD17B10HSD11B1 | |
| SCHEMBL31247729 | 0.73 | GRM5 (0.54) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL31247663 | 0.73 | JAK2 (0.52) | JAK2JAK1TYK2JAK3MAP4K4 | |
| SCHEMBL31300242 | 0.72 | HTT (0.50) | JAK2JAK1TYK2JAK3MAP4K4 | |
| SCHEMBL31247375 | 0.72 | HTT (0.50) | JAK2JAK1TYK2JAK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12358904-B2 | Inhibitors of TYK2 | Atomwise Inc. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| US-20240417396-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-19 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417396-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885ALDH1A1 4785/4885HPGD 4472/4885 |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | KDM4E 642/4885ALDH1A1 4552/4885HPGD 4439/4885 |
| US-12358904-B2 | Inhibitors of TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885ALDH1A1 4785/4885HPGD 4472/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | KDM4E 302/4885ALDH1A1 4785/4885HPGD 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.